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Abstract
Background: Many cancer patients are interested in complementary and integrative medicine during and after
regular cancer treatment. Given the high number of users it is important that physicians and patients engage in
a dialog about useful complementary and integrative medicine therapies during cancer treatment.
In a prospective, multi-center, cluster-randomized evaluation study we will develop, implement and evaluate a
training program for oncology physicians advising their patients on complementary and integrative medicine. The
main objective of the study is to evaluate whether training physicians in a blended-learning approach (e-learning
+ skills-training workshop) in providing advice to their cancer patients on complementary and integrative medicine,
in addition to handing out an information leaflet about reputable websites, has different effects on the outcomes
of patients, physicians, and their interaction level, compared to only giving out the information leaflet.
Methods/design: Forty-eight oncology physicians will be included into a cluster-randomized trial to either
participate or not in the blended-learning training. Physicians will then advise 10 cancer patients each, resulting in
480 patients participating in the trial. The blended learning consists of nine units of up to 45 min of e-learning and
18 units of up to 45 min of on-site skills-training workshop focusing. Outcomes will be measured on the physician,
patient, and physician-patient-interaction level.
Discussion: A blended-learning program for oncology physicians to advise their cancer patients in a systematic
way and a reasonable time frame on complementary and integrative medicine will be evaluated in depth in a large
cluster-randomized trial.
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Background
Complementary and integrative medicine (CIM) inter-
ventions have received increasing amounts of attention
and are often used as self-management techniques for
patients hoping to positively influence their cancer treat-
ment [1, 2]. Motives mentioned by many patients were
improving the immune system and increasing the effect-
ivity of cancer treatment, reducing side effects and
generally taking on an active part in their own treatment
process [1, 3]. In line with this, some data show that the
use of CIM during cancer care has increased consistently
worldwide from only 25% of patients using it in the
1970s to 49% after 2000 [4].
Often patients face the variety of available CIM
therapies without professional advice. The evidence for
many CIM therapies is absent or inconclusive and new
treatment forms appear frequently, highlighting the im-
portance that patients get valid and understandable in-
formation. However, although patients wish to receive
CIM information from their physicians [3, 5], many in-
dependently seek suitable treatments via numerous on-
line sources. The uncovered full spectrum of faulty,
unclear or evidence-based information may affect pa-
tients when making decisions in favor of, or against,
CIM [6, 7]. To achieve the optimal course of treatment,
patients hence should discuss their interest in CIM with
their oncology physician so that patients’ expectations
towards CIM can be taken into account during consulta-
tions and the use of CIM can be brought into line with
cancer treatment [3, 8, 9].
Despite the necessity of it, many patients do not disclose
their CIM use to their oncology physician [1, 10, 11]. Rea-
sons for this can be explained on both sides of the
patient-physician relationship. On the one hand, patients
often do not find it necessary to discuss CIM with their
respective physician, thus underestimating the harms or
risks of interaction with their cancer treatment [12, 13].
Furthermore, patients anticipate and experience the physi-
cian’s disinterest in the topic and a negative response [14].
On the other hand, physicians might feel uncomfortable
when providing information about evidence of CIM treat-
ments [15]. Qualitative research in this field has shown
that oncologists often regard the concept of CIM as being
well outside their field [16]. However, health professionals
in the field of oncology are often confronted with this
topic. Therefore, the majority realize the great importance
of being well informed in this area [15, 17].
Physicians’ willingness to be trained on CIM approaches
shows that training programs in this area are strongly
required [15]. A cluster-randomized pilot trial by our
group showed that training physicians in providing advice
during CIM-designated consultations scores highly for pa-
tient satisfaction and may be especially beneficial for phy-
sicians less experienced in CIM. However, physicians have
reported that an additional consultation about CIM is
time-consuming and that including long CIM consulta-
tions into everyday practice poses a problem [18].
To the best of our knowledge, a structured training
program for oncology physicians in advising cancer pa-
tients via feasible consultations about CIM has not been
established nor has there been a rigorous evaluation of
CIM training at different levels (physicians, patients or
their interaction) in Germany.
The Competence Network Complementary Medicine in
Oncology (KOKON) is a collaborative research project in
Germany (www.kompetenznetz-kokon.de). Funded by the
German Cancer Aid, KOKON has aimed to improve
knowledge and information transfer for CIM in oncology
since 2012. This paper describes the KOKON-KTO study
as part of the KOKON Competence Network.
The main objective of this study is to evaluate whether
training physicians using a blended-learning approach
(e-learning + workshop) to provide advice to their can-
cer patients on CIM, in addition to handing out an in-
formation leaflet about reputable websites, has different
effects on the outcomes of patients, physicians and their
interaction level, compared to only giving out the infor-
mation leaflet.
Methods/design
Design
In a prospective, multi-center, cluster-randomized, two-
armed study, 48 physicians will be included and ran-
domized by cluster (hospital departments or private
practices) into two groups, one that will be trained
(intervention group) and the other that will not be
trained (control group).
In the intervention group, oncology physicians will
provide CIM advice to 10 cancer patients each and pro-
vide an information leaflet on reputable websites to their
patients while oncology physicians in the control group
will provide an information leaflet to their 10 recruited
patients without giving additional advice on CIM.
As this study uses an exploratory approach, no sample
size has been formally calculated. Based on logistical
considerations, the anticipated physicians’ learning curve
and in order to be able to give indications for further
studies in this field, recruiting 400–480 patients seems
reasonable.
Physician recruitment and eligibility
The oncology physicians participating in the KOKON-
KTO study will be recruited from hospital departments
treating cancer patients (e.g., breast centers, departments
for gynecology, ear, nose, throat departments, etc.) and
private practices. Oncology physicians in private practices
are part of the German health care insurance system and
treat patients who are statutorily and privately insured.
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The described recruitment sites are hereinafter referred to
as “hospital departments” and “private practices.”
From each hospital department two oncologists will
have to be eligible and will be counted as a cluster. The
48 oncology physicians (24 working with specialization
on gynecologic oncology) will be recruited from hospital
departments (50%) and private practices (50%).
To allow heterogeneity, half of the participating oncol-
ogy physicians will have a focus in gynecological oncol-
ogy, while the other half will have focuses in other
cancer entities. In Germany, gynecology is one of the
surgical specialties of medicine. However, gynecology
also includes a wide range of conservative treatment
methods, such as hormone therapy, counseling,
contraception methods, and reproductive health. All
physicians with a specialization in gynecology partici-
pating in this study will have to work with cancer
patients on a regular basis in hospital departments or
private practices.
Recruitment will take place in the following federal
states in Germany: Baden-Württemberg, Bavaria,
Berlin, Hamburg, and North Rhine-Westphalia. Heads
of hospital departments as well as representatives of
private practices will be contacted by letters. The
heads of hospital departments will be invited to send
two oncology physicians each and the representatives
of private practices will be invited directly to partici-
pate. Oncology physicians will be screened for their
eligibility after receiving the study documents and
subsequently will be included in the study on a
“first-come first-served” basis.
Oncology physicians will be eligible if they fulfill
the following selection criteria (based on self-reported
information): specialization in the field of oncology,
little knowledge of CIM, no previous structured train-
ings in CIM in the field of oncology, only a little ex-
perience in advising cancer patients on CIM,
sufficient resources to conduct 10 consultations with
cancer patients during their usual working hours,
ability to take part in the on-site skills-training work-
shop in Berlin as well as good German language
skills. Physicians will provide written informed con-
sent to the study team. Physicians will retain the right
to withdraw from the intervention and the study at
any time during the course of the study. However,
the study team will contact physicians to document
the reasons for withdrawal.
Physician of both groups will receive 34 CME points
by the German Doctors Association after the successful
completion of the KOKON-KTO training.
We decided not to include radiation oncologists
in the study because of their different medical
specialization and to reduce the variation in oncol-
ogy settings.
Patient recruitment and eligibility
Cancer patients interested in advice on CIM will be re-
cruited by the participating oncology physicians following
a first-come first-served principle. For recruitment pur-
poses, the physicians will receive study information mate-
rials provided by the central study office. Patients will be
eligible if they meet the following criteria: age ≥ 18 years, di-
agnosed with cancer, being treated in the participating hos-
pital department/practice, the cancer treatment has been
already planned or is ongoing, good German language
skills, interested in the topic evaluated by the question:
“Are you interested in getting information about com-
plementary medicine within cancer care from your
oncology physician?” Patients with cognitive impair-
ments (based on the subjective assessment of the
physician that complex information cannot be trans-
ferred) will be excluded.
During the trial period, all patients will receive their
usual cancer treatment and supportive care by their
oncology care team. CIM consultations will be con-
ducted as an addition to patients’ planned or ongoing
cancer therapy. Patients will give oral and written in-
formed consent to their participating oncology physi-
cians. Patients will retain the right to withdraw from
the study at any time during the study. However, the
study team will contact them to record reasons for
withdrawal.
Random allocation procedures
The cluster-randomization into both groups will occur on
a hospital department or private practice level. Whereas
each private practice will provide only one oncology phys-
ician (cluster 1), hospital departments will each provide
two oncology physicians (cluster 2). Randomization of
clusters will be stratified by type of center (hospital depart-
ment or practice) and specialization (gynecology, other
oncology) using an allocation ratio of 1:1. After fulfilling
the inclusion criteria and obtaining written informed con-
sent from all participating physicians as well as, if neces-
sary the heads of hospital departments, centers will be
randomized by the study team. The randomization list will
be generated by a statistician not otherwise involved in
the study using SAS, version 9.4 (SAS Institute, Cary, NC,
USA). The list will be transferred into a secured database
(Microsoft Office Access 2010; Microsoft Corporation,
Redmond, WA, USA) and be hidden behind the inter-
face so that it will not be accessible to anyone involved in
the random allocation or treatment. The order of
randomization for both strata (gynecologist and oncolo-
gists) will follow the first-come first-served principle.
Intervention procedures
The intervention of the study consists of two phases for
the intervention group: the first phase with the focus on
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the physician level and the second phase as an inter-
action between physicians and their patients.
Phase I: physicians of the intervention group will receive
a blended-learning training, which should qualify them to
provide structured advice to their cancer patients on CIM
in a KOKON-KTO consultation. The training and its
content (knowledge about CIM and the KOKON-KTO
consultation manual) have been developed in collabor-
ation with KOKON project partners, taking findings of a
previous pilot study [18] and published structured recom-
mendations for discussing CIM in cancer care [19] into
account. The subsequent development process included
international experts and stakeholder engagement as well
as peer review and testing phases. With the aim to in-
crease feasibility and integration into daily medical work,
the consultations were designed not to exceed a time
frame of 20min.
The KOKON-KTO training consists of the following
components (Appendix):
1. KOKON-KTO e-learning: the KOKON-KTO e-
learning contains information about CIM and the
evidence and safety aspects of various treatments.
Knowledge about therapies and supporting evidence,
as well as safety aspects, will be measured by multiple-
choice tests based on predetermined learning objec-
tives. Moreover, the systematic KOKON-KTO con-
sultation will be taught by using video sequences,
audio and text information. The e-learning consists of
nine obligatory lessons (up to 45min each) and can be
completed in approximately 6–7 h
2. Workshop: a 2-day on-site skills-training workshop
consisting of 18 lessons (up to 45 min each) will
train practical skills and implement the theoretical
knowledge to provide CIM information in an em-
pathic and systematic way to the patient. Exercises
include dealing with unclear or missing evidence
and typical, authentic challenges for preparing
decision-making about CIM. Using a variety of
teaching methods (e.g., role playing, consultations
with standardized patients) typical consultation sit-
uations based on clinical case vignettes will be
trained. Every workshop participant will practice a
complete KOKON-KTO consultation about CIM in
cancer care with a standardized patient
Learning objectives: after the KOKON-KTO training,
oncology physicians should be able to compare different
CIM and other supportive therapies and to lead a
KOKON-KTO consultation adapted to context. After
the KOKON-KTO e-learning oncology physicians should
be able to (1) classify the needs and challenges of CIM in
oncology, (2) differentiate between various CIM and
other supportive therapies and (3) apply essential
elements of the KOKON-KTO consultation in exam-
ples. After the on-site skills-training workshop, oncol-
ogy physicians should be able to (1) apply knowledge
on CIM and other supportive therapies, (2) imple-
ment elements of the KOKON-KTO conversation in
role plays, (3) deal practically with the challenges of
CIM and other supportive therapies, and (4) conduct
a KOKON-KTO consultation about CIM with stan-
dardized patient.
The information leaflet that physicians will hand over to
patients was developed by a multi-professional expert
team (psychologists, oncologists, public health researcher)
with knowledge of CIM in oncology, who selected three
websites (https://www.kokoninfo.de/komplementaermedi-
zin, https://www.krebsinformationsdienst.de/behandlung/
unkonv-methoden-index.php, https://www.onkopedia.-
com/de/my-onkopedia/guidelines) providing information
in the German language and one international website
written in the English language (https://www.mskcc.org/
cancer-care/diagnosis-treatment/symptom-management/
integrative-medicine/herbs). All recommended websites
provide information on CIM treatments, their possible
applications and effectiveness, as well as their safety
(e.g., interaction with cancer treatments). The infor-
mation leaflet displays details on language, level of
CIM education, and level of information provided.
This way, patients will be able to choose the website
most suitable for them.
Furthermore, a criteria list will be prepared that can
be handed over by oncology physicians to patients to en-
able the latter to select trustworthy providers of CIM.
This list will be developed in a modified expert consen-
sus procedure involving multiple stakeholders. It will be
made available to oncology physicians in the interven-
tion group to use it within the KOKON-KTO consulta-
tions and can be handed out optionally to patients.
Phase II: after the training, each physician will conduct
consultations following the KOKON-KTO consultation
manual with 10 of their own patients. After each
KOKON-KTO consultation, physicians will provide their
patients with the information leaflet for reputable web-
sites about CIM in oncology.
For the control group, the intervention of this study
will consist of three phases:
Phase I: physicians of the control group will receive
instructions delivered via KOKON-KTO e-learning on
how to provide the information leaflets for reputable
websites about CIM in oncology to their cancer pa-
tients. The 45min e-learning lesson will explain the
handover of the leaflet and will describe possible chal-
lenges that can occur during this short consultation
Phase II: physicians of the control group will provide
10 of their recruited patients with the information
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leaflet along with a short face-to-face consultation
(2–5 min) about the content of the leaflet
Phase III: after completion of the follow-up assessment
of patients, the control group will receive the same
blended-learning KOKON-KTO training. Afterwards,
the control group will be asked to advise patients on
CIM. Qualitative interviews will be subsequently con-
ducted with all physicians after having KOKON-KTO
consultations
Both groups of physicians will be trained for the
study procedures prior to the study. Furthermore,
physicians will be trained at several time points
(KOKON-KTO e-learning, skills-training workshop,
KOKON-KTO consultation manual, study materials)
for whom the KOKON-KTO consultation is appropri-
ate. The oncology physicians will, therefore, learn that
the KOKON-KTO consultation is only suitable for
patients who show an interest in CIM and for whom
the wish to use CIM is not an expression for another
need such as fear of death or the need for informa-
tion on cancer treatment. The study flow chart is
shown in Fig. 1.
Quantitative outcomes
Outcomes are based on an international consensus
process including a workshop (Berlin, February 2017)
and written rounds. During the workshop experts agreed
that a single primary outcome would not be sufficient to
capture all relevant information. Therefore, several out-
comes on three different levels were suggested (phys-
ician, patient, and physician-patient-interaction level).
Then, main and secondary outcomes were selected for
each level (Table 1).
In addition, Situational Judgment Tests, a method of
contextual competence diagnostics in a realistic context,
will be developed and used as part of the KOKON-KTO
e-learning for physicians in the control group. Excerpts
from case vignettes will be used to describe specific chal-
lenges in the physician-patient interaction when discuss-
ing CIM. The given situation will be assessed by the
participants selecting the most appropriate behavioral
option(s) for them [19].
The main outcomes at the physician level are the per-
ceived consultation skill competency (time frame: weeks
7–30) and the perceived stress reaction (time frame:
weeks 7–30) in a consultation situation, which will be
measured by two self-developed standardized instru-
ments tailored to the specific KOKON-KTO consult-
ation situation. The perceived consultation skill
competency will be measured for three predefined emo-
tional situations, which could occur during a consult-
ation about CIM (overburden, tension, and discomfort
with the consultation situation). Physicians will rate their
perceived consultation skills on a numerical rating scale
(NRS) from 0 to 10. Physician’s perceived stress reac-
tions in a consultation situation will be measured on a
NRS 0–10 as well.
Main outcomes (Table 1) on the patient level (time
frame: week 2) will be as follows: issues related to the
communication between the patient and their treating
oncology physician will be measured by the EORTC
communication module (EORTC-QLQ-COMU26)
[20], which is intended to assess communication
between patients and health professionals. It includes
26 items, which mainly assess behaviors related to
communication and is organized into six scales and
four individual items. To measure patient satisfaction
with the information given on cancer treatment, two
scales of the “Patient Satisfaction with Cancer Treat-
ment Education (PS-CaTE)” questionnaire in German
developed by the British Columbia Cancer Agency
will be used [21]. Satisfaction with information re-
garding vitamins, herbs and complementary therapy
as well as satisfaction with information sources and
the that way information is provided will be measured
on a 5-point Likert scale (“strongly disagree” to
“strongly agree”). Furthermore, the “Preparation for
Decision Making (PrepDM)” questionnaire [22] will
be used to evaluate decision processes related to the
preparation of patients for decision-making and
engaging in dialogue with their practitioners. The
10-item questionnaire includes questions like: “Did
this educational material help you recognize that a
decision needs to be made?” and “Did this educa-
tional material prepare you to make a better
decision?”
The main outcomes at the physician-patient-interaction
level (Table 1) are the performance during communication
with standardized patients (time frame: week 6). Oncology
physicians participating in the study will undergo a
KOKON-KTO consultation with standardized patients
trained for study purposes. The KOKON-KTO consult-
ation is intended to closely follow the KOKON-KTO
consultation manual. Hence, the performance will be
measured by a self-developed inventory tailored to this
manual. Furthermore, interactive and communicative
competencies will be rated using the “Munich Physician
Patient Interaction Inventory (MAPI)” [23], which
asks, for instance, whether the physician let the
patient speak out or created a friendly consultation
atmosphere. Both inventories will be rated by two in-
dependent raters who are present at the consultation
with a standardized patient without influencing the
interaction. Furthermore, qualitative interviews will be
conducted as face-to-face-conversations with stan-
dardized patient to gain deeper insight into patient
perspective.
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Demographic and clinical information and further variables
Physicians will be asked to supply details regarding
their age, sex, level of occupational qualification,
and number of years of experience with cancer pa-
tients. Furthermore, they will be asked to answer a
questionnaire about the cancer treatment of each of
the patients included in the study (current diagno-
sis, time since diagnosis, status of diagnosis, present
and planned cancer treatment, intention of cancer
treatment).
Fig. 1 KOKON-KTO study flow chart. aIncludes questions about knowledge about complementary and integrative medicine (CIM). bIncludes
provision of medical information by MD. *Oncology physicians (MD, medical doctor), **Patients
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Table 1 Outcomes
Domain Method of measurement Metric Time frame
Physician level
Main outcome Perceived consultation skill competency NRS Fully disagree (0) to fully
agree (10)
Weeks 7–30
Perceived stress reaction NRS Fully disagree (0) to fully
agree (10)
Weeks 7–30
Further outcomes Level of CIM knowledge in cancer care Multiple-choice questions 5 options, multiple response Enrollment,
Week 6
Expectations regarding the effectiveness
of CIM
5-point Likert scale Fully agree to fully disagree Enrollment,
Week 6
Expectations regarding the side effects
of CIM
NRS very safe (0) to not safe at
all (10)
Enrollment,
Week 6
Personal attitude towards CIM Situational Judgment Test 5 options, 1 response Enrollment,
Week 6
Personal attitude towards CIM after
knowing the results of the Situational
Judgment Test that are based on
expert ratings
Situational Judgment Test 5 options, 1 response Week 6
Application of the project-developed
communication manual about CIM in
oncology
Multiple-choice questions 5 options, 1 response Weeks 1–6
Handling challenges in consultations
about CIM therapies
Situational Judgment Test 5 options, 1 response Enrollment,
Week 6
Implementability of the manual-based
consultation in the treating oncology
physicians’ daily work
6-point Likert scale Very good to not at all Weeks 7–30,
Duration of the CIM consultation Time Minutes Weeks 7–30
Reasons for communications longer
than 20 min
Open-ended question Weeks 7–30
Patient level
Main outcomes Communication between physician
and patient.
EORTC-QLQ-COMU26 Not at all (1) to fully agree (4) Week 2
Patient satisfaction PS-CaTE Not at all (1) to fully agree (5) Week 2
Preparation for decision-making PrepDM Not at all (1) to very much (5) Week 2
Further outcomes Knowledge of CIM in cancer care Multiple-choice questions 5 options, 1 response − t1,
Week 2
Use of the recommended reputable
websites about CIM in cancer care
and subjectively experiences usefulness
of the website
NRS Very helpful (0) to not helpful
at all (10)
Week 2
Physician’s attitude towards CIM NRS Fully disagree (0) to fully
agree (10)
Week 2
Use of CIM and subjective therapeutic
success
Multiple-choice questions 3 options: positive, negative,
not sure
Week 2
Physician-patient-interaction level
Main outcomes Performance during communication
with standardized patients
NRS Fully disagree (0) to fully
agree (10)
Week 7
Interactive and communicative
competencies
MAPI Fully disagree (0) to fully
agree (5)
Week 7
CIM complementary and integrative medicine, EORTC-QLQ-COMU26 EORTC communication module, MAPI Munich Physician Patient Interaction Inventory, NRS
numerical rating scale, PrepDM Preparation for Decision Making, PS-CaTE Patient Satisfaction with Cancer Treatment Education
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Patients will be asked about their past use of CIM and
about the empathy of their physicians [24].
Quantitative data collection
All physicians will be asked to answer questionnaires at
several time points. First, by using a web-based survey
prior to the e-learning, oncology physicians will provide
their baseline information. Second, the physicians will
complete a paper-pencil questionnaire after each com-
munication with/handout of the information leaflet to
10 of their patients. Third, each physician will answer a
paper-pencil questionnaire after completing the inter-
vention with all 10 patients. Furthermore, physicians will
be asked to evaluate the blended learning and to provide
medical information about each patient after including
them in the study. Patients will complete paper-pencil
questionnaires at baseline (prior to the consultation/
handout of the information leaflet) and 2 weeks after the
consultation/handout of the information leaflet. For the
physician-patient-interaction level, a systematic external
rating by two independent raters will be conducted dur-
ing the on-site skills-training workshop. For this, a con-
sultation with a standardized patient will be conducted.
In the case of no or little recruitment, the study team
will contact the physicians to offer information and sup-
port on how to improve recruitment or how to integrate
the consultation into daily routine.
A Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) Figure and Checklist
for this study protocol are provided in Fig. 2 and
Additional file 1, respectively.
Data management, storage and security
The data will be managed according to the Standard Op-
erating Procedures (SOPs) and the quality management
protocol of the coordinating center (Institute for Social
Medicine, Epidemiology, and Health Economics, certi-
fied according to DIN EN ISO 9001:2015). An identifica-
tion number (ID), not containing aspects that allow
identification (e.g., initials or date of birth) will be
assigned to each study participant (medical doctors
(MDs) and patients). Data collection, data entry and data
processing will be based on this ID. The data from the
paper questionnaires will be entered in this pseudony-
mized form into a database programmed by a data man-
ager of the Institute for Social Medicine, Epidemiology
and Health Economics of the Charité – Universitätsme-
dizin Berlin. All data will be stored for at least 10 years.
The archiving will be pseudonymized. The data will be
collected using SoSci-Survey software and written ques-
tionnaires. In e-Learning (Moodlerooms), questions will
also be asked in order to ascertain the development of
the participants’ level of knowledge and experience.
Within the scope of the study, only anonymized data will
be evaluated. The data from the online survey will be
transferred as CSV files and stored in a database at the
coordinating center. The telephone interviews will be re-
corded with a digital sound-recording device, transcribed
anonymously and stored using the ID.
Statistics
All statistical analyses will be considered exploratory. Suit-
able summary statistics and graphical methods will be used
to describe characteristics of the sample at baseline. Mean
values and standard deviations (median and percentiles, if
applicable) will be calculated for metric variables, frequen-
cies and percentages for categorical variables.
Differences in the outcomes between the two treat-
ment groups will be analyzed by multilevel models
(analysis of covariance (ANCOVA) type or logistic-
Fig. 2 Content of the KOKON-KTO schedule of enrollment, interventions, and assessments according to the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT) Statement. *Oncology physicians (MD, medical doctor), **Patients
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regression-type model). Models will include the phys-
ician as a random (clustering) effect, the stratification
variables including type of center (hospital depart-
ment or private practice) and specialization
(gynecology or other oncology) as fixed effects, and
the respective baseline value (if available) as a covari-
ate. The multilevel structure of the data is due to pa-
tients treated within a physician, and physicians
working within a cluster. However, due to the small
number of physicians per cluster (one to two), the
cluster (center) will not be taken into the model. For
the treatment effect, adjusted mean values with 95%
confidence intervals will be reported. In addition, a
blinded analysis of baseline data will be performed to
determine relevant baseline differences between the
intervention and control groups. For sensitivity ana-
lysis, we will repeat the aforementioned models with
adjustment for these variables. Furthermore, whether
a different intensity of e-learning use (e.g., different
increases in knowledge, duration of use) affects the
outcomes (“dose-response relationship”) will be inves-
tigated. All P values will be considered explorative. A
detailed statistical analysis plan (SAP) will be devel-
oped prior to any data analysis. Data analysis will be
performed in SAS Version 9.4 or higher (SAS Inc.,
Cary, NC, USA) or SPSS Version 23 or higher.
Qualitative data collection
A qualitative substudy will complement the quantitative
findings. Qualitative semi-standardized telephone or on-
line video interviews will be conducted with all oncology
physicians of the control group who experienced both
conditions (consultation with and without KOKON-
KTO training). Interviews will occur 8 to 10 weeks after
the on-site skills-training workshop of the control condi-
tion. The qualitative data will allow a fuller picture of
the consultation experience.
Moreover, face-to-face-interviews will be conducted
with all standardized patients after the on-site skills-
training workshop. They will be interviewed in one-
on-one, face-to-face, semi-structured interviews with
one investigator to approach and explore patients’
perspective during KOKON-KTO consultations.
Qualitative analysis
Control oncology physicians will be asked questions
focusing on their personal experience when giving
advice to their patients before and after the training.
Standardized patients will be asked about their
experience when getting advice from oncology physi-
cians during the KOKON-KTO consultations. Tran-
scripts will be imported into MAXQDA [25]. Data
will be analyzed through content analysis according to
Mayring and Flick [26, 27], deductive and inductive
coding strategies will be combined. Deductive codes
are predefined by the research team according to the
semi-structured interview guideline. The coding of
other subcategories of data analysis will follow a con-
tinuous process of extracting codes from conducted
interviews and discussions among the team members.
Patients’ quotes will be translated from German to
English. Conducted interviews will be interpreted by
two qualitative researchers in order to approximate
reliability. Differences in the interpretation of the data
will be discussed with the study team.
Ethics
The study will be performed in agreement with the
Declaration of Helsinki and has been approved by the
relevant local ethics boards (Ethics Committee of Char-
ité – Universitätsmedizin Berlin, Medical Association
Hamburg, Medical Association Baden-Wuerttemberg,
Medical Association Nord Rhine, Ethics Committee of
the Medical Association of Westphalia-Lippe, Ethics
Committee at the Medical Faculty of Würzburg, Ethics
Committee of the Medical Faculty of Heidelberg, Ethics
Commission of the Albert-Ludwigs-University of Frei-
burg). In addition, issues regarding data protection were
approved by the local data protection officer at Charité
– Universitätsmedizin Berlin. All study participants will
provide oral and written informed consent.
Physicians will have to spend a considerable amount
of time for the study including e-learning, workshop,
assessment, and KOKON-KTO consultations. There is a
risk that oncology physicians will feel overwhelmed by
the training and study procedures. A user-centric ap-
proach will be used for the study documents and the
KOKON-KTO blended learning. An experienced team
will prepare the respective materials.
Standardized consultations in workshops or role plays
can be perceived as stressful by some physicians and
physicians in the control group may be burdened by the
fact that they will only hand over a flyer with recom-
mendation for reputable websites within a short consult-
ation without a communication training. However,
physicians in the control group will be prepared for this
situation in a 45-min e-learning.
Patients will have to invest time for the study to
complete questionnaires and there might be patients
who will be tempted to use alternative strategies which
interfere with their cancer treatment. To prevent these,
patient assessments will be minimized. Moreover, physi-
cians will be trained to inform about evidence-based
CIM approaches and that CIM treatment, if used, should
be complementary and not alternative to cancer treat-
ments. Furthermore, they will mention, where applic-
able, the risks of interactions.
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Governance, quality assurance, and safety
This study is part of a larger network project (Compe-
tence Network Complementary Medicine in Oncology)
that is managed by a steering group that consists of
seven members. The principle investigator of this project
is also a member of this steering group. Relevant design
changes and safety issues as well as progress of the pro-
ject according to predefined milestones will be discussed
in the steering group that has monthly conference calls.
Furthermore, the network project has an advisory board
that can also provide advice for this trial.
The trial will be conducted according to the Standard
Operating Procedures (SOPs) and the quality manage-
ment protocol of the coordinating center (Institute for
Social Medicine, Epidemiology, and Health Economics,
certified according to DIN EN ISO 9001:2015). Data
quality will be checked by a data manager following
SOPs. The institute receives annual audits according to
DIN EN ISO 9001:2015.
Dissemination
We aim to publish the study results in international
peer-reviewed medical journals. Moreover, we plan to
present results nationally and internationally at oncol-
ogy, gynecology, and CIM conferences and to provide
website information.
Discussion
This trial will help to determine the effects of a
blended-learning training for a CIM consultation with
cancer patients. We will evaluate outcomes at the physi-
cian-patient-interaction level. The study and the training
that we aim to evaluate contain several unique aspects.
First, this is a large cluster-randomized trial that will in-
vestigate a structured training on this topic for oncology
physicians in Germany. Furthermore, the consultation
about CIM in cancer care should not be longer that 20
min so it can be integrated into usual care. One of
our previous studies demonstrated that oncology phy-
sicians found it difficult to integrate stand-alone time-
intensive CIM consultations into their daily routine.
However, physicians also stated that they found the
additional time to talk with their patients satisfying
[19]. Therefore, our concept will address this chal-
lenge. To overcome it, we will tailor the training to
the needs of oncology physicians when giving advice
to their own patients. This will make the consultation
less time-consuming.
Another unique point is the broad investigation of ef-
fects on different levels. We will ask not only oncology
physicians about their opinion on the training and the
consultations but also the patients. Furthermore, we will
analyze the physician-patient interaction as this was a
major recommendation produced by our expert work-
shop on outcomes.
Our study protocol has several distinctive aspects in-
cluding that cancer patients not only obtain their cancer
care in hospital departments but also in private practices
in Germany. We aim to include both types of institu-
tions and will ask oncology physicians with varying
specializations (oncology as well as gynecology) to par-
ticipate in our study. Moreover, physicians from five
different federal states will be asked to participate. In
addition, we will include only CIM-inexperienced
physicians in our study. Based on our previous pilot
study we assume that they might gain a greater bene-
fit from training on communicating with patients
about CIM [18].
This study is subject to limitations. First, it should be
mentioned that a 20-min consultation is not sufficient to
cover all possible issues arising around CIM in oncology as
well as other challenges that might occur during this con-
sultation. The focus of this study is to train physicians for a
more general approach that can be easily implemented in
their daily medical work. For CIM consultations that are
more complex and might have a different focus, existing
guidelines and other settings can be applied [28].
Even though the consultations and the consultation
manual were planned carefully and after consideration
of expert opinions, it cannot be guaranteed that the dis-
cussion will be applicable to cancer patients in practice
and under real-life conditions without restrictions. How-
ever, these doubts should be dispelled by the testing of
the KOKON-KTO consultation manual by experienced
oncology physicians who are unfamiliar with the training
in advance. Furthermore, oncology physicians participat-
ing in the KOKON-KTO study will have exemplary con-
sultations with standardized patients before
conducting consultation with their own patients.
The KOKON-KTO training will be the first to be
tested in a randomized controlled trial with patients
under real-life conditions.
There is a risk that oncology physicians in the control
group may feel overwhelmed in the consultation situation
due to the low level of CIM training. However, in routine
care they frequently receive questions on CIM by their
cancer patients. Being able to provide a leaflet might not
solve the situation but perhaps improve it. The interviews
and the completion of the interview assessments will take
place during the working hours of the physicians. In the
previous study, no aspects that we would have categorized
as side effects of the consultations were documented. Fu-
ture studies might think about appropriate safety mea-
sures for this type of interventions.
In addition, the study will not examine whether the
physicians actually adhere to the manual and training
and follow the recommendations when conducting
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their consultations. However, e-learning sections on
indication-specific CIM therapies are intended to increase
the knowledge about effectiveness and safety and, therefore,
the quality of CIM advice in the KOKON-KTO con-
sultations. Furthermore, the on-site skills-training
workshop including a standardized patient setting will
train the oncology physicians to adhere to the
KOKON-KTO consultation manual. Neither physi-
cians nor patients can be blinded regarding group al-
location because of the different training content and
consultation settings, and bias due to this cannot be
excluded.
As another limitation of the study, the KOKON-KTO
training, consisting of a 6-h e-learning and a 2-day on-site
skills-training workshop, is relatively time-consuming and
is, therefore, only suitable for physicians who are inter-
ested in the topic and in giving CIM advice to patients.
With regard to the measurement of the data, mainly
self-administered questionnaires with inherent limita-
tions will be applied. Moreover, the consultations con-
ducted by the oncology physicians with standardized
patients will not be recorded on video but merely
assessed by a systematic external rating. This procedure
results from our previous study [18], in which the par-
ticipating oncology physicians were partially disapprov-
ing of video recordings. KOKON-KTO consultations
will only be observed and objectively rated during the
workshop at the end of the training. This study will not
include radiation oncologists because of their different
oncology setting. This way it is easier to develop the ma-
terials targeted to the treatment situation for our
blended learning. For future trainings these materials
might be added and evaluated.
In the case of questions regarding patient’s satisfaction
with the consultation, ceiling effects may also occur, which
have already occurred in our previous study [18]. There-
fore, it might be important to get a better understanding
of the meaning of satisfaction for this type of patients.
However, since we will use outcomes on several levels we
decided not to include a broader evaluation of satisfaction.
Our study will provide evidence on a training program
(e-learning + workshop) for oncology physicians on advising
their patients on CIM, and the study will offer data on the
program’s effects in comparison to only handing out an
information leaflet about reputable websites. Furthermore,
the study will not only provide new information about the
effects on outcomes at the physician level but also at the pa-
tient, and the patient-physician-interaction level.
Trial status
The trial is currently in the process of recruiting. Re-
cruitment of physicians started in June 2017 and was
completed in December 2017. Patient recruitment
started in April 2018.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 Checklist. (DOC 124 kb)
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e-learning Complementary
medicine for
cancer
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• Use, needs, and challenges
of CIM in oncology
1
CIM therapies • Whole medical systems
• Nutrition
• Exercises
• Mindfulness
• Phytotherapy
• Vitamins and supplements
6
KOKON-KTO
consultation
• KOKON-KTO consultation
manual
• Example videos
2
Workshop Day 1 • Role plays
• Impulse lectures
• Exchange of experience
• Audio statements
• Discussion rounds
• Mistletoe
8
Day 2 • Challenges arising during
CIM consultations by
observing two role plays
with an expert as
consultation-leading
physician
• Nutrition
• Standardized KOKON-KTO
consultation
8
CIM complementary and integrative medicine
Helmer et al. Trials           (2019) 20:90 Page 11 of 12
Medical Association Hamburg (MC-368/17), Medical Association Baden-
Wuerttemberg (B-F-2017-10), Medical Association Nord Rhine (2417337),
Ethics Committee of the Medical Association of Westphalia-Lippe (2017–624-
b-S), Ethics Committee at the Medical Faculty of Würzburg (274/17_z-me),
Ethics Committee of the Medical Faculty of Heidelberg (S-550/2017), Ethics
Commission of the Albert-Ludwigs-University of Freiburg (531/17). Informed
consent will be obtained from all participants collected by their treating
oncology physician. Changes in the study protocol will be reported to the
local Ethics Committees as amendments. Moreover, participants will be
individually contacted in written and oral form by the study team to ensure
implementation of any changes.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Institute for Social Medicine, Epidemiology, and Health Economics, Charité –
Universitätsmedizin Berlin, corporate member of Freie Universität Berlin,
Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin,
Germany. 2Department of Psychosomatic Medicine, Center for Internal
Medicine and Dermatology, Charité – Universitätsmedizin Berlin, corporate
member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin
Institute of Health, Berlin, Germany. 3Department of Internal Medicine,
Division of Oncology and Hematology, Paracelsus Medical University,
Klinikum Nuremberg, Nuremberg, Germany. 4Institute for Complementary
and Integrative Medicine, University of Zurich and UniversityHospital Zurich,
Zurich, Switzerland. 5Center for Integrative Medicine, University of Maryland
School of Medicine, Baltimore, MD, USA.
Received: 5 July 2018 Accepted: 10 January 2019
References
1. Molassiotis A, et al. Use of complementary and alternative medicine in
cancer patients: a European survey. Ann Oncol. 2005;16(4):655–63.
2. Hammer MJ, et al. Self-management for adult patients with cancer: an
integrative review. Cancer Nurs. 2015;38(2):E10–26.
3. Kessel KA, et al. Use of Complementary and Alternative Medicine (CAM) as
part of the oncological treatment: survey about patients’ attitude towards
CAM in a university-based oncology center in Germany. PLoS One. 2016;
11(11):e0165801.
4. Horneber M, et al. How many cancer patients use complementary and
alternative medicine? Integr Cancer Ther. 2012;11(3):187–203.
5. Oskay-Ozcelik G, et al. Breast cancer patients’ expectations in respect of the
physician-patient relationship and treatment management results of a
survey of 617 patients. Ann Oncol. 2007;18(3):479–84.
6. Evans M, et al. Decisions to use complementary and alternative medicine
(CAM) by male cancer patients: information-seeking roles and types of
evidence used. BMC Complement Altern Med. 2007;7:25.
7. Broom A, Tovey P. The role of the Internet in cancer patients’ engagement
with complementary and alternative treatments. Health (London). 2008;
12(2):139–55.
8. Holmes MM, Bishop FL, Calman L. “I just Googled and read everything”:
exploring breast cancer survivors’ use of the Internet to find information on
complementary medicine. Complement Ther Med. 2017;33:78–84.
9. Frenkel M, Cohen L. Effective communication about the use of
complementary and integrative medicine in cancer care. J Altern
Complement Med. 2014;20(1):12–8.
10. Tautz E, et al. Use of complementary and alternative medicine in breast
cancer patients and their experiences: a cross-sectional study. Eur J Cancer.
2012;48(17):3133–9.
11. Juraskova I, et al. Discussing complementary therapy use with early-stage
breast cancer patients: exploring the communication gap. Integr Cancer
Ther. 2010;9(2):168–76.
12. Vickers KA, Jolly KB, Greenfield SM. Herbal medicine: women’s views,
knowledge and interaction with doctors: a qualitative study. BMC
Complement Altern Med. 2006;6(1):40.
13. Arthur K, et al. Reasons to use and disclose use of complementary medicine
use—An insight from cancer patients. Cancer Clin Oncol. 2013;2(2):81–92.
14. Robinson A, McGrail MR. Disclosure of CAM use to medical practitioners: a
review of qualitative and quantitative studies. Complement Ther Med. 2004;
12(2):90–8.
15. Winslow C, Shapiro H. Physicians want education about complementary
and alternative medicine to enhance communication with their patients.
Arch Intern Med. 2002;162(10):1176–81.
16. Guethlin C, Holmberg C, Klein G. Oncologists’ experiences of discussing
complementary and alternative treatment options with their cancer
patients. A qualitative analysis. Support Care Cancer. 2016;24(9):3857–62.
17. Klein GE, Guethlin C. Information and training needs regarding
complementary and alternative medicine: a cross-sectional study of cancer
care providers in Germany. Integr Cancer Ther. 2018;17(2):380–7.
18. Blödt S, et al. A consultation training program for physicians for
communication about complementary medicine with breast cancer
patients: a prospective, multi-center, cluster-randomized, mixed-method
pilot study. BMC Cancer. 2016;16:843.
19. Kiessling C, et al. Development and validation of a computer-based
situational judgement test to assess medical students’ communication skills
in the field of shared decision making. Patient Educ Couns. 2016;99(11):
1858–64.
20. Arraras JI, et al. EORTC QLQ-COMU26: a questionnaire for the assessment of
communication between patients and professionals. Phase III of the module
development in ten countries. Support Care Cancer. 2017;25(5):1485–94.
21. Liekweg A, et al. Psychometric assessment and application of a
questionnaire measuring patient: satisfaction with information on cancer
treatment. Pharm World Sci. 2005;27(2):96–103.
22. Bennett C, et al. Validation of a preparation for decision making scale.
Patient Educ Couns. 2010;78(1):130–3.
23. Casar D. Evaluation eines Arzt-Patien-Interaktions-Trainings im Krankenhaus
anhand von Selbst- und Fremdbeoachtungen. In: Medizinische Fakultät.
Ludwig-Maximilians-Universität München; 2009.
24. Neumann M, et al. Psychometric evaluation of the German version of the
“Consultation and Relational Empathy” (CARE) measure at the example of
cancer patients. Psychother Psychosom Med Psychol. 2008;58(1):5–15.
25. Software V. MAXQDA Analytics Pro. Berlin: VERBI; 2016.
26. Mayring P. In: überarbeitete Auflage, editor. Qualitative Inhaltsanalyse
Grundlagen und Techniken. 9. Weinheim: Beltz Verlag; 2007.
27. Flick U. Doing triangulation and mixed methods. The Sage qualitative
research kit. Vol. 2nd. Los Angeles: Sage; 2018.
28. Schofield P, et al. Effectively discussing complementary and alternative
medicine in a conventional oncology setting. Communication
recommendations for clinicians. Patient Educ Couns. 2010;79(2):143–51.
Helmer et al. Trials           (2019) 20:90 Page 12 of 12
